Long intergenic non-coding RNA, regulator of reprogramming (LINC-ROR) over-expression predicts poor prognosis in renal cell carcinoma.
NANOG
POU5F1
SOX2
long intergenic non-coding RNA
regulator of reprogramming
renal cell carcinoma
Journal
Archives of medical science : AMS
ISSN: 1734-1922
Titre abrégé: Arch Med Sci
Pays: Poland
ID NLM: 101258257
Informations de publication
Date de publication:
2021
2021
Historique:
received:
19
04
2018
accepted:
14
07
2018
entrez:
2
8
2021
pubmed:
17
5
2019
medline:
17
5
2019
Statut:
epublish
Résumé
Long intergenic non-coding RNA, regulator of reprogramming (LINC-ROR) is a newly identified cytoplasmic long non-coding RNA (lncRNA) implicated in cell longevity and apoptosis. We aimed in the current work for the first time to investigate the association of the expression profiles of LINC-ROR and three stem-related transcriptional factors with clinicopathological data and their impact on renal cell carcinoma (RCC) progression in a sample of RCC patients. Expression levels of LINC-ROR and stemness-related factors: SOX2, NANOG, and POU5F1 were detected in 60 formalin-fixed, paraffin-embedded tissues, and their paired adjacent non-cancer tissues ( The genes studied were markedly up-regulated in RCC (medians and interquartile ranges were 30.3 (1.84-235.5), 10.2 (1.84-53.9), 5.39 (0.94-23.5), and 12.5 (1.61-43.2) for Collectively, aberrant LINC-ROR and pluripotent gene expression may be recognised as prognostic markers for RCC. Future functional studies are highly recommended to validate the study findings.
Identifiants
pubmed: 34336029
doi: 10.5114/aoms.2019.85201
pii: 93419
pmc: PMC8314397
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1016-1027Informations de copyright
Copyright: © 2019 Termedia & Banach.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Nat Rev Genet. 2014 Jan;15(1):7-21
pubmed: 24296535
Tumour Biol. 2017 Jun;39(6):1010428317705790
pubmed: 28635401
Hepatology. 2012 Sep;56(3):1004-14
pubmed: 22473773
Dev Cell. 2013 Apr 15;25(1):1-2
pubmed: 23597480
Pathol Oncol Res. 2016 Oct;22(4):733-40
pubmed: 27071407
Cell Res. 2013 Mar;23(3):340-50
pubmed: 23208419
Front Genet. 2015 Feb 27;6:72
pubmed: 25774169
Arch Med Sci. 2016 Jun 1;12(3):473-8
pubmed: 27279836
Nat Rev Cancer. 2014 Aug;14(8):568-73
pubmed: 25030952
Tumour Biol. 2017 Apr;39(4):1010428317698366
pubmed: 28443494
Nat Rev Nephrol. 2017 Aug;13(8):496-511
pubmed: 28691713
Oxid Med Cell Longev. 2017;2017:3269379
pubmed: 29104726
Stem Cells Int. 2016;2016:1797692
pubmed: 26697072
Arch Med Sci. 2017 Oct;13(6):1249-1254
pubmed: 29181054
Nat Rev Dis Primers. 2017 Mar 09;3:17009
pubmed: 28276433
Cell Physiol Biochem. 2016;40(1-2):219-229
pubmed: 27855392
Nat Genet. 2010 Dec;42(12):1113-7
pubmed: 21057500
Med Sci Monit. 2017 Feb 20;23:919-928
pubmed: 28216611
Nat Rev Cancer. 2014 Apr;14(4):216-7
pubmed: 24658270
Mol Cell. 2015 Apr 16;58(2):362-70
pubmed: 25801169
EMBO J. 2012 Feb 1;31(3):522-33
pubmed: 22193719
Breast Cancer. 2017 Mar;24(2):326-335
pubmed: 27300169
Oncol Rep. 2016 Mar;35(3):1657-63
pubmed: 26676719
Dev Cell. 2013 Apr 15;25(1):69-80
pubmed: 23541921
Chin J Cancer. 2013 Sep;32(9):483-7
pubmed: 23419197
Genome Biol. 2015 Dec 09;16:275
pubmed: 26654108
Mol Med. 2016 Oct;22:653-663
pubmed: 27623812
Trends Cancer. 2017 Feb;3(2):126-136
pubmed: 28718443
Nature. 2011 Aug 28;477(7364):295-300
pubmed: 21874018
Nucleic Acids Res. 2016 Apr 20;44(7):3059-69
pubmed: 26656491
RNA. 2010 Feb;16(2):324-37
pubmed: 20026622
Nat Rev Urol. 2014 Sep;11(9):517-25
pubmed: 25112856